SCHEMBL255243

SCHEMBL255243

Nc1ccccc1Nc1ccc(Cl)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.70
KDM4E B2RXH2 3/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
ALOX15 P16050 2/20 0.70
TP53 P04637 1/20 0.70
APP P05067 1/20 0.70
HPGD P15428 1/20 0.70
SNCA P37840 1/20 0.70
BLM P54132 1/20 0.70
HSD17B10 Q99714 1/20 0.70
GAA P10253 7/20 0.69
ALDH1A1 P00352 4/20 0.69
MEN1 O00255 4/20 0.69
KMT2A Q03164 4/20 0.69
LMNA P02545 2/20 0.69
CYP1A2 P05177 1/20 0.69
CYP2D6 P10635 1/20 0.69
CYP2C9 P11712 1/20 0.69
CYP2C19 P33261 1/20 0.69
TDP1 Q9NUW8 3/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977454 0.89 MAPT (0.61) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL4607773 0.89 MAPT (0.86) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL6658275 0.87 MAPK13 (0.79) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL9396738 0.83 MAPT (0.91) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL4647245 0.83 MAPT (0.76) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL1636651 0.83 MAPT (1.00) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL29388147 0.82 MAPT (1.00) MAPTKDM4ESMN1; SMN2ALOX15TP53
SCHEMBL217480 0.82 MAPT (1.00) MAPTKDM4ESMN1; SMN2ALOX15TP53
Methane SCHEMBL28002603 0.81 MAPT (0.96) MAPTKDM4ESMN1; SMN2ALOX15TP53
Hydrochloric Acid SCHEMBL29809096 0.80 MAPT (0.95) MAPTKDM4ESMN1; SMN2ALOX15TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114507189-A Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis 余述南 2022-05-17 CN claimed
CN-112521339-A Preparation method of chlorphenazine 山西立业制药有限公司 2021-03-19 CN claimed
CN-120441496-A Preparation method of clofazimine key intermediate 仁合益康集团有限公司 2025-08-08 CN disclosed
CN-109293587-B Preparation method of clofazimine and intermediate thereof 浙江华海立诚药业有限公司 2023-06-16 CN disclosed
CN-109293587-B Preparation method of clofazimine and intermediate thereof 浙江华海立诚药业有限公司 2023-06-16 CN disclosed
CN-114507189-A Chemically synthesized bulk drug and application thereof in treating tuberculosis and drug-resistant tuberculosis 余述南 2022-05-17 CN disclosed
CN-114380767-A Thiazole amide compound containing diphenylamino group and preparation method and application thereof 安徽理工大学 2022-04-22 CN disclosed
CN-113454057-A Intermediate for preparing phenazine derivative and preparation method thereof ST制药株式会社 2021-09-28 CN disclosed
US-20210115489-A1 NOVEL MEDIATOR KIKKOMAN CORPORATION (JP) 2021-04-22 US disclosed
US-20210115489-A1 NOVEL MEDIATOR KIKKOMAN CORPORATION (JP) 2021-04-22 US disclosed
CN-112521339-A Preparation method of chlorphenazine 山西立业制药有限公司 2021-03-19 CN disclosed
US-4358579-A FIBERS, FILMS, LAMINATES, COATINGS STANDARD OIL COMPANY (INDIANA) (US) 1982-11-09 US disclosed
US-4315854-A Chromium and cobalt complex amino hydroxy azomethine dyes CIBA-GEIGY CORPORATION (US) 1982-02-16 US disclosed
US-4296114-A 3,4-Dihydro-3-oxopyrido[2,3-b]-pyrazines, compositions and use thereof FISONS LIMITED (GB) 1981-10-20 US disclosed
EP-0018939-A1 1:2 Metal complex dyestuffs of azomethines, process for their preparation and process for dyeing and printing by using these dyestuffs CIBA-GEIGY AG (CH) 1980-11-12 EP disclosed
EP-0008864-A1 Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them FISONS plc (GB) 1980-03-19 EP disclosed
EP-0008226-A2 Phenyl-alkanoic acid derivatives, the preparation thereof and pharmaceutical compositions containing them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-02-20 EP disclosed
US-4009994-A Process and product of optical brightening with quaternized benzofuranyl-benzimidazoles CIBA-GEIGY CORPORATION (US) 1977-03-01 US disclosed
US-3940417-A Quaternised benzofuranyl-benzimidazoles CIBA-GEIGY CORPORATION (US) 1976-02-24 US disclosed
US-3931215-A OPTICAL BRIGHTENERS HOECHST AKTIENGESELLSCHAFT (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115489-A1 NOVEL MEDIATOR MPO, EPX, LPO MAPT 4015/4885KDM4E 2284/4885SMN1; SMN2 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.